Gambogic acid induces death of K562 cells through autophagy and apoptosis mechanisms
Authors:
- 27 March 2015
- journal article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 56 (10) , 2953-2958
Abstract
This study was aimed to detect the effects of gambogic acid (GA) on the growth of chronic myelogenous leukemia (CML) K562 cells. Our results showed that GA induced the accumulation of autophagic vacuoles and up-regulation of two autophagy-related proteins (Beclin 1 and LC3). GA also induced down-regulation of mRNA levels of BCR-ABL fusion gene and SQSTM1/sequestosome 1 (p62) protein levels. After treatment by chloroquine (CQ) and pan caspase inhibitor Z-VAD-FMK (PC), both GA-induced autophagy and apoptosis were inhibited. Our study demonstrates that GA may induce cell death through autophagy and apoptosis pathways in CML K562 cells. A cross-talk mechanism exists between GA-induced autophagy and apoptosis. However, the mechanism of GA for inducing autophagy and apoptosis need further clarification.Keywords
This publication has 31 references indexed in Scilit:
- Chronic myeloid leukaemia as a model of disease evolution in human cancerNature Reviews Cancer, 2007
- Oncogenic signaling: new insights and controversies from chronic myeloid leukemiaJournal of Experimental Medicine, 2007
- New Insights into the Pathophysiology of Chronic Myeloid Leukemia and Imatinib ResistanceAnnals of Internal Medicine, 2006
- Mechanisms of BCR–ABL in the pathogenesis of chronic myelogenous leukaemiaNature Reviews Cancer, 2005
- Mechanisms of transformation by the BCR-ABL oncogene: new perspectives in the post-imatinib eraLeukemia Research, 2004
- JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesisLeukemia, 2004
- Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALLLeukemia, 2003
- A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemiasBlood, 2002
- Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II studyBlood, 2002
- Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia ChromosomeNew England Journal of Medicine, 2001